Lv11
100 积分 2025-09-11 加入
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
1天前
待确认
miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer
21天前
已完结
The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention
1个月前
已完结
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
2个月前
已完结
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
2个月前
已完结
NK Cells Mediate T-cell Inflammation in the Tumor Microenvironment
2个月前
已完结
Preclinical Development of MGC028, an ADAM9-Targeted, Glycan-Linked, Exatecan-Based Antibody–Drug Conjugate for the Treatment of Solid Cancers
2个月前
已完结
Safety, Efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque psoriasis - Results from a randomized phase II trial
2个月前
已关闭
Frontline: Optimal T cell activation requires the engagement of CD6 and CD166
3个月前
已完结
皖公网安备34019202002308
